BRAF and thyroid cancer: As for immunotherapy, PD-1/PD-L1 inhibitors, such as pembrolizumab and nivolumab, are being investigated in combination with other targeted therapies, like BRAF inhibitors, to improve the immune response in patients with refractory thyroid cancer.